CN1191064C - 含有苯乙酰谷氨酰胺、苯乙酰异谷氨酰胺和/或其衍生物的药物组合物 - Google Patents

含有苯乙酰谷氨酰胺、苯乙酰异谷氨酰胺和/或其衍生物的药物组合物 Download PDF

Info

Publication number
CN1191064C
CN1191064C CNB99811314XA CN99811314A CN1191064C CN 1191064 C CN1191064 C CN 1191064C CN B99811314X A CNB99811314X A CN B99811314XA CN 99811314 A CN99811314 A CN 99811314A CN 1191064 C CN1191064 C CN 1191064C
Authority
CN
China
Prior art keywords
general formula
compound
day
patients
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB99811314XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1319010A (zh
Inventor
斯坦尼斯劳·R·伯辛斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN1319010A publication Critical patent/CN1319010A/zh
Application granted granted Critical
Publication of CN1191064C publication Critical patent/CN1191064C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
CNB99811314XA 1998-07-23 1999-07-02 含有苯乙酰谷氨酰胺、苯乙酰异谷氨酰胺和/或其衍生物的药物组合物 Expired - Fee Related CN1191064C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/121567 1998-07-23
US09/121,567 US6258849B1 (en) 1998-07-23 1998-07-23 Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CNB2004100616005A Division CN100400039C (zh) 1998-07-23 1999-07-02 用于治疗肿瘤疾病的组合物及其应用
CNA2004100032827A Division CN1605334A (zh) 1998-07-23 1999-07-02 组合物在制备用于治疗肿瘤疾病的药物中的用途

Publications (2)

Publication Number Publication Date
CN1319010A CN1319010A (zh) 2001-10-24
CN1191064C true CN1191064C (zh) 2005-03-02

Family

ID=22397538

Family Applications (3)

Application Number Title Priority Date Filing Date
CNB99811314XA Expired - Fee Related CN1191064C (zh) 1998-07-23 1999-07-02 含有苯乙酰谷氨酰胺、苯乙酰异谷氨酰胺和/或其衍生物的药物组合物
CNA2004100032827A Pending CN1605334A (zh) 1998-07-23 1999-07-02 组合物在制备用于治疗肿瘤疾病的药物中的用途
CNB2004100616005A Expired - Fee Related CN100400039C (zh) 1998-07-23 1999-07-02 用于治疗肿瘤疾病的组合物及其应用

Family Applications After (2)

Application Number Title Priority Date Filing Date
CNA2004100032827A Pending CN1605334A (zh) 1998-07-23 1999-07-02 组合物在制备用于治疗肿瘤疾病的药物中的用途
CNB2004100616005A Expired - Fee Related CN100400039C (zh) 1998-07-23 1999-07-02 用于治疗肿瘤疾病的组合物及其应用

Country Status (20)

Country Link
US (2) US6258849B1 (enExample)
EP (1) EP1098643B1 (enExample)
JP (2) JP2002521329A (enExample)
KR (4) KR100399658B1 (enExample)
CN (3) CN1191064C (enExample)
AT (1) ATE257378T1 (enExample)
AU (1) AU759278B2 (enExample)
BR (1) BR9912356A (enExample)
CA (1) CA2336945C (enExample)
DE (1) DE69914084T2 (enExample)
DK (1) DK1098643T3 (enExample)
EA (1) EA004179B1 (enExample)
ES (1) ES2214866T3 (enExample)
ID (1) ID28160A (enExample)
IL (1) IL140848A (enExample)
NZ (1) NZ509244A (enExample)
PL (1) PL213698B1 (enExample)
PT (1) PT1098643E (enExample)
WO (1) WO2000004894A2 (enExample)
ZA (1) ZA200100622B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127419A (en) * 1998-11-23 2000-10-03 Burzynski; Stanislaw R. Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis
DK1313697T3 (da) 2000-08-29 2006-04-10 Nobex Corp Immunregulatoriske forbindelser, derivater deraf samt anvendelse deraf
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
US7087219B2 (en) * 2003-05-28 2006-08-08 Stanislaw R. Burzynski Toothpaste containing anticancer agents
US20060246016A1 (en) * 2003-05-28 2006-11-02 Burzynski Stanislaw R Toothpaste containing anticancer agents
US7772108B2 (en) * 2004-06-25 2010-08-10 Samsung Electronics Co., Ltd. Interconnection structures for semiconductor devices and methods of forming the same
WO2006014549A2 (en) * 2004-07-07 2006-02-09 Nobex Corporation Synthesis of azo bonded immunoregulatory compounds
CA2575367A1 (en) * 2004-07-28 2006-02-23 Board Of Regents, The University Of Texas System 3-halo-2-oxopropionate salts and esters as novel anticancer agents
DE602005019319D1 (de) 2004-11-26 2010-03-25 Ucl Business Plc Zusammensetzungen mit ornithin und phenylacetat oder phenylbutyrat zur behandlung von hepatischer enzephalopathie
US20060205818A1 (en) * 2005-03-08 2006-09-14 Burzynski Stanislaw R Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives
PT2413924T (pt) 2009-04-03 2018-01-04 Ocera Therapeutics Inc Fenil acetato de l-ornitina e métodos de preparação do mesmo
EA025735B1 (ru) 2009-06-08 2017-01-30 ЮСиЭл БИЗНЕС ПиЭлСи Способ лечения портальной гипертензии с использованием l-орнитина в сочетании по меньшей мере с одним из соединений, выбранных из фенилацетата и фенилбутирата
EA028395B1 (ru) 2010-10-06 2017-11-30 Осера Терапьютикс, Инк. Способы получения фенилацетата l-орнитина
BR112017010761B1 (pt) 2014-11-24 2022-10-18 Ucl Business Plc Tratamento de doenças associadas à ativação de célula estrelada hepática com o uso de terapias de redução de amônia
JP6990170B2 (ja) 2015-08-18 2022-01-12 オセラ セラピューティクス， インコーポレイテッド Ｌ－オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる筋肉喪失の治療および予防
EP3397960B1 (en) * 2015-12-30 2020-01-29 Société des Produits Nestlé S.A. Method for determining fat free body mass
US10624869B2 (en) * 2017-05-08 2020-04-21 Stanislaw R. Burzynski Methods for the treatment of recurrent glioblastoma (RGBM)
AU2018266357B2 (en) 2017-05-11 2022-12-08 Ocera Therapeutics, Inc. Processes of making L-ornithine phenylacetate
US11344521B2 (en) 2017-06-12 2022-05-31 Burzynski Research Institute, Inc. Methods for the treatment of leptomeningeal disease
US11607397B2 (en) * 2017-06-12 2023-03-21 Stanislaw R. Burzynski Methods for the treatment of leptomeningeal disease
US20230190694A1 (en) * 2021-11-03 2023-06-22 Stanislaw R. Burzynski Compositions for and methods of precision cancer treatment
CN116019798B (zh) * 2022-07-20 2024-03-12 中南大学湘雅二医院 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用
CN116491472B (zh) * 2022-12-14 2024-07-26 上海交通大学医学院附属第九人民医院 苯乙酰谷氨酰胺在构建慢性创面动物模型中的用途
WO2024263966A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating pancreatic cancer
WO2024263963A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating head and neck cancer
WO2024263960A2 (en) * 2023-06-21 2024-12-26 Burzynski Stanislaw R Compositions comprising antineoplastons and methods of treating lung cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4470970A (en) 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
US5244922A (en) 1990-09-04 1993-09-14 Burzynski Stanislaw R Methods for treating viral infections
US5254587A (en) 1990-09-04 1993-10-19 Burzynski Stanislaw R Methods for treating AIDS
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
JP4320052B2 (ja) 1996-05-14 2009-08-26 スタニスロー、アール、バージンスキー 著しく改善された抗腫瘍活性によるリポソーム抗腫瘍療法

Also Published As

Publication number Publication date
WO2000004894A2 (en) 2000-02-03
PT1098643E (pt) 2004-05-31
EP1098643B1 (en) 2004-01-07
AU759278B2 (en) 2003-04-10
CN1605334A (zh) 2005-04-13
CN1660061A (zh) 2005-08-31
US6943192B2 (en) 2005-09-13
KR20030027087A (ko) 2003-04-03
CA2336945C (en) 2008-11-18
KR20030027088A (ko) 2003-04-03
BR9912356A (pt) 2001-04-17
EA200100168A1 (ru) 2001-08-27
KR100414587B1 (ko) 2004-01-13
AU4854299A (en) 2000-02-14
WO2000004894A3 (en) 2000-04-27
ATE257378T1 (de) 2004-01-15
KR20030027089A (ko) 2003-04-03
KR100417101B1 (ko) 2004-02-05
NZ509244A (en) 2004-02-27
DE69914084D1 (de) 2004-02-12
DK1098643T3 (da) 2004-05-24
JP2002521329A (ja) 2002-07-16
US6258849B1 (en) 2001-07-10
IL140848A (en) 2005-05-17
DE69914084T2 (de) 2004-10-28
HK1037142A1 (en) 2002-02-01
US20010044466A1 (en) 2001-11-22
ZA200100622B (en) 2002-06-26
EP1098643A2 (en) 2001-05-16
ES2214866T3 (es) 2004-09-16
PL213698B1 (pl) 2013-04-30
CN100400039C (zh) 2008-07-09
PL345959A1 (en) 2002-01-14
CA2336945A1 (en) 2000-02-03
JP2011051993A (ja) 2011-03-17
ID28160A (id) 2001-05-10
EA004179B1 (ru) 2004-02-26
IL140848A0 (en) 2002-02-10
KR100417100B1 (ko) 2004-02-05
CN1319010A (zh) 2001-10-24
KR100399658B1 (ko) 2003-09-29
KR20010071025A (ko) 2001-07-28

Similar Documents

Publication Publication Date Title
CN1191064C (zh) 含有苯乙酰谷氨酰胺、苯乙酰异谷氨酰胺和/或其衍生物的药物组合物
CN1498103A (zh) 肽类化合物用于治疗非神经性炎性疼痛的新用途
CN1228694A (zh) 使用锰化合物降低抗肿瘤药物心脏毒性的方法
CN1531435A (zh) 抑制血管生成的方法
CN104105482B (zh) 红细胞生成素产生促进剂
CN1489460A (zh) 炎症性疾病治疗预防剂
EP4045058A1 (fr) Utilisation de nictotinamide mononucléotide (nmn) pour la prevention et/ou le traitement de la polyarthrite rhumatoïde et compositions correspondantes
CA3133204A1 (en) Drug and method for treating or preventing diabetes complications using same drug
HK1074771A (en) Use of composition in the manufacture of a medicament for treating neoplastic disease
WO2009081991A1 (ja) 脳虚血障害治療剤
CN1490329A (zh) 咪唑啉取代的苯氧乙酰寡肽类衍生物，它们的合成及在医学中的应用
CN1490328A (zh) 咪唑啉取代的苯氧乙酰寡肽类化合物，它们的合成及在医学中的应用
CN1041723C (zh) N,n'－二乙酰胱氨酸的有机盐
CN1620312A (zh) 慢性肾脏疾病治疗药物
EP4065129A1 (fr) Utilisation de composés pour la prévention et/ou le traitement de la spondylarthrite ankylosante et compositions correspondantes
HK1037142B (en) Phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate for the treatment of neoplastic diseases
CN1747727A (zh) 围术期血糖值上升抑制剂
CN1630533A (zh) 高血压症治疗药
JP2003012553A (ja) 免疫系未成熟動物投与用及び免疫系成熟動物投与用の癌予防剤
MXPA99000255A (en) Treatment regimen for the administration of phenylacetilglutamine, phenylacetilisoglutamine and / or fen acetate

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050302

Termination date: 20180702

CF01 Termination of patent right due to non-payment of annual fee